ABVX (ABVX) Stock Price & Analysis
ABVX (ABVX) rose 1.17% to USD 102.72 as of June 10, 2026 at 02:15 UTC, according to Nexqual real-time market data.
ABVX last closed at USD 101.53; the session ranged USD 96.84–103.04 on volume of 1,173,338 shares. Market capitalization is $8.19B, with a 52-week range of USD 5.69–148.83 (NGM). Source: Nexqual, June 10, 2026 at 02:15 UTC.
Key Statistics (as of June 10, 2026 at 02:15 UTC)
| Price | USD 102.72 |
|---|---|
| Change | ▲ 1.17% (up) |
| Previous Close | USD 101.53 |
| Open | USD 101.4 |
| Day Range | USD 96.84 – 103.04 |
| 52-Week Range | USD 5.69 – 148.83 |
| Volume | 1,173,338 shares |
| Market Cap | $8.19B |
| Exchange | NGM |
Technical Analysis (ABVX)
Nexqual's technical model rates ABVX "STRONG SELL" based on 0 bullish and 5 bearish signals across 124 daily candles, as of June 10, 2026 at 02:15 UTC.
| Overall Signal | STRONG SELL |
|---|---|
| RSI (14) | 44.39 (neutral) |
| vs SMA50 | Below (USD 116.55) |
| MACD | -4.88 (negative) |
Analyst Ratings (ABVX)
Wall Street analysts rate ABVX "Buy" based on 11 analysts, with a mean price target of USD 149.09 (range USD 90–187), per Nexqual as of June 10, 2026 at 02:15 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 11 |
| Mean Target | USD 149.09 |
| High Target | USD 187 |
| Low Target | USD 90 |
| Buy / Hold / Sell | 10 / 1 / 0 |
Earnings (ABVX)
| Next Earnings Date | 2026-03-23 |
|---|---|
| EPS Estimate | USD -0.66 |
| Revenue Estimate | $813,470 |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -0.71 vs est -0.81 ▲ beat |
| 2025-12-31 | USD -1.18 vs est -1.05 ▼ miss |
| 2025-09-30 | USD -2.47 vs est -0.79 ▼ miss |
| 2025-06-30 | USD -0.89 vs est -0.95 ▲ beat |
Source: Nexqual, June 10, 2026 at 02:15 UTC.
Financials & Fundamentals (ABVX)
| Total Revenue | $4.92M |
|---|---|
| Revenue Growth (YoY) | +35.20% |
| Gross Margin | +100.00% |
| Operating Margin | -4183.70% |
| Profit Margin | +0.00% |
| ROE | -157.07% |
| Debt / Equity | 7.96 |
| Current Ratio | 8.25 |
| Total Cash | $491.55M |
| Total Debt | $34.21M |
| Free Cash Flow | $-114.47M |
Source: Nexqual, June 10, 2026 at 02:15 UTC.
Financial Health Score (ABVX)
Nexqual rates ABVX's overall financial health "Weak" across five dimensions, as of June 10, 2026 at 02:15 UTC.
| Growth | Critical — Revenue -63% YoY (annual), sharp decline |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Strong — $492M cash vs $34M debt, net cash position |
| Cash Flow | Weak — FCF negative: -$114M, burning cash |
| Efficiency | Critical — ROE -157%, ROA -44.7% |
Ownership (ABVX)
| Insider Ownership | +0.00% |
|---|---|
| Institutional Ownership | +70.56% |
| Shares Outstanding | 79.77M |
| Float | 58.23M |
| Short % of Float | +3.88% |
Source: Nexqual, June 10, 2026 at 02:15 UTC.
Leadership (ABVX)
ABVX is led by Marc M. P. de Garidel (age 67), CEO & Director, per Nexqual as of June 10, 2026 at 02:15 UTC.
| CEO & Director | Marc M. P. de Garidel (age 67) |
|---|---|
| EVP, CFO & Board Secretary | Didier Blondel (age 61) |
| Senior Vice President of Investor Relations | Patrick Malloy |
| Executive Vice President of Process Development & Manufacturing | Jerome Denis |
| Senior Vice President of Finance | Hema Keshava |
Major Backers & Investors (ABVX)
Notable institutional backers of ABVX include TCG Crossover Management, LLC, UBS Group AG, Darwin Global Management, Ltd., according to Nexqual as of June 10, 2026 at 02:15 UTC.
Active Investors
| Investor | Stake |
|---|---|
| TCG Crossover Management, LLC | 8.13% |
| UBS Group AG | 5.71% |
| Darwin Global Management, Ltd. | 4.35% |
| Morgan Stanley | 2.14% |
| Vestal Point Capital, LP | 1.88% |
| Caligan Partners, LP | 1.83% |
| Adar1 Capital Management, LLC | 1.75% |
| Westfield Capital Management Co LP | 1.66% |
Source: Nexqual, June 10, 2026 at 02:15 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| CELC | Celcuity Inc. | USD 92.59 | ▲ 4.88% |
| PRAX | Praxis Precision Medicines, Inc | USD 250.33 | ▼ 1.44% |
| ALMS | Alumis Inc. | USD 20.01 | ▲ 4.98% |
| MLYS | Mineralys Therapeutics, Inc. | USD 24.18 | ▲ 2.07% |
| GPCR | Structure Therapeutics Inc. | USD 41.25 | ▲ 9.77% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 02:15 UTC. This page is informational and not investment advice.